Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075932 | 1.00 | HDAC3 (0.44) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL16280323 | 0.88 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15075864 | 0.88 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15075823 | 0.87 | GLS (0.46) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL16280334 | 0.84 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15059149 | 0.84 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15075811 | 0.83 | PSMB5 (0.47) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15058653 | 0.83 | PSMB5 (0.47) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL15075955 | 0.80 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL16280553 | 0.80 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793900-B1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING SA (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | HDAC3 3021/4885HDAC1 895/4885HDAC2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.